IREN
IREN Limited
There isn't enough reported data to score IREN yet.
PROV
Provident Financial Holdings, Inc.
PROV's fundamentals are mixed, but it looks expensive: trading at 18x earnings, above its usual 15x. Analysts expect earnings growth.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
PROV Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
PROV's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like PROV.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
PROV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $11.99 | -34% |
| Forward | 13x | $18.24 | — |
| Fair | 15x | $15.03 | -18% |
| Expensive | 18x | $18.75 | +2.8% |
| Current | 18x | $18.24 | — |
Historical ranges are pointers, not guarantees.
PROV's PE is in its expensive range at 18x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its fair range.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
PROV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect PROV's earnings to grow and its profitability to improve, with its revenue holding steady.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
PROV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.35 | +32% |
| Q3 2026 | $1.03 | +14% |
| Q2 2026 | $1.03 | +11% |
| Q1 2026 | $0.92 | -5.2% |
| Q4 2025 | $0.99 | +8.8% |
| Q3 2025 | $0.90 | -17% |
| Q2 2025 | $0.93 | -12% |
| Q1 2025 | $0.97 | -4.9% |
| Q4 2024 | $0.91 | -19% |
PROV has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN has the edge over PROV on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
PROV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +8.5% |
| Q2 2026 | $10.6M | +8.5% |
| Q1 2026 | $9.9M | -2.4% |
| Q4 2025 | $9.8M | +2.5% |
| Q3 2025 | $9.7M | +2.4% |
| Q2 2025 | $9.8M | -1.6% |
| Q1 2025 | $10.1M | +7.6% |
| Q4 2024 | $9.6M | -0.5% |
PROV's revenue has picked up after three years of holding roughly level: $11M last quarter, up 8.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -7.5 points |
| Q2 2026 | 28% | +4.1 points |
| Q1 2026 | 19% | -6.9 points |
| Q4 2025 | 21% | +8.1 points |
| Q3 2025 | 28% | -0.2 points |
| Q2 2025 | 24% | -4.2 points |
| Q1 2025 | 26% | +3.8 points |
| Q4 2024 | 13% | -19 points |
PROV has the edge over IREN on profitability, with a higher operating margin.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
PROV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3M | +74% |
| Q2 2026 | $3.3M | +53% |
| Q1 2026 | $1.7M | -47% |
| Q4 2025 | $1M | +236% |
| Q3 2025 | $2.5M | +2.7% |
| Q2 2025 | $2.2M | +$3M |
| Q1 2025 | $3.3M | +27% |
| Q4 2024 | $307K | +$749K |
PROV has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
PROV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.9% | -189K shares |
| 1 year | -5% | -332K shares |
| 3 years | -10% | -733K shares |
| 5 years | -17% | -1.3M shares |
| Available history | -18% | -1.4M shares |
PROV has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.7M |
| Q2 2026 | $1.9M |
| Q1 2026 | $1.5M |
| Q4 2025 | $1.5M |
| Q3 2025 | $1.1M |
| Q2 2025 | $1.2M |
| Q1 2025 | $801,000 |
| Q4 2024 | $1M |
PROV spent $7M buying back its own shares over the past year, up 64% from the year before.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
PROV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.1x | Net Cash |
| Q2 2026 | -3.6x | Net Cash |
| Q1 2026 | -4.4x | Net Cash |
| Q4 2025 | -4.1x | Net Cash |
| Q3 2025 | -4.0x | Net Cash |
| Q2 2025 | -4.3x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -3.7x | Net Cash |
PROV has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like PROV.
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
PROV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 45.7 | Neutral |
PROV's weekly RSI is 64 (neutral) and its Stochastic is 46 (neutral).
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
PROV PE vs Financial Services Sector
| Metric | PROV | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 13x | 36% above |
| PE % | 79 | 63 | 16 pts above |
PROV is trading at 18x earnings, a 36% premium to the Financial Services sector's median of 13x.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
PROV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.2 | 0% above |
| 20 week MA | $18.0 | 1.1% above |
| 50 week MA | $17.1 | 6.7% above |
| 100 week MA | $16.2 | 12% above |
| 200 week MA | $14.9 | 23% above |
PROV has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.
PROV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.0 | $15.8 | -28% |
| 2021 | $15.8 | $16.7 | +5.7% |
| 2022 | $16.7 | $13.8 | -17% |
| 2023 | $13.8 | $12.6 | -8.4% |
| 2024 | $12.6 | $15.9 | +26% |
| 2025 | $15.9 | $16.1 | +1.1% |
| 2026 YTD | $16.1 | $18.2 | +13% |
PROV has the edge over IREN on returns for 2026, with the stronger performance.